Faculty180 - Vita and Individual Profile Data Sheet

Daniel Handley, PhD, MS, BA

Fall 1980 - Fall 2120

Professor I

[email protected]

Current Position

Position: Program Director, Master of Science in Genetics/Genomics

Biography

Dr. Handley serves as Founding Director of the Master of Science in Human Genetics and Genomics degree program at SCU. He also serves on the Board of Directors of Predictive Oncology, Inc. (NASDAQ: POAI) where he is chair of the Governance and Nomination Committee. Previously, he served as the Chief Scientific Officer of CTGRI in Florida and held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University. He has served as the Chief Scientific Officer of Life-SEQ, LLC, a clinical genomic sequencing consulting company, as Chief Scientific Officer for Advanced Healthcare Technology Solutions, Inc., as a senior researcher at the Procter & Gamble Co., a senior administrator and laboratory manager at the David Geffen School of Medicine at UCLA, and as a founding technology innovator for the National Genetics Institute in Los Angeles, California.

Degrees

2008

M.S., Logic and Computation, Carnegie Mellon University, Pittsburgh, Pennsylvania, United StatesDissertation: Evaluating Machine Learning Algorithms Used to Infer Gene Regulatory Networks

Ph.D., Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United StatesDissertation: Systems Approach to Analyzing the TGF/SMAD3 Gene Regulatory Pathways in A549 Cells

1990

B.A., Biophysics, Johns Hopkins University, Baltimore, Maryland, United States

Post-Graduate Training

Type: Post-Doctorate, Magee-Womens Research Institute, Post-Doctorate, Genomics, Pittsburgh, Pennsylvania, United States, April 2008, April 2010

Work Experience

2015 - 2019

Courtesy Faculty, Florida Gulf Coast University, Fort Myers, Florida, United States

2013 - 2018

Chief Scientific Officer, Life-SEQ LLC, Bostom, Massachusetts, United States

2012 - 2019

Chief Scientific Officer, Clinical and Translational Genome Research Institute, Fort Myers, Florida, United States

2008 - 2013

Strategic Advisory Board Member, Brainstage, Inc., Pittsburgh, Pennsylvania, United States

1994 - 2000

Senior Research Associate, Procter and Gamble Company, Cincinnati, Ohio, United States

1991 - 1994

Laboratory Manager/Senior Administrative Analyst, UCLA School of Medicine, Los Angeles, California, United States

Scholarly Contributions and Creative Productions

Journal Article

Completed/Published

Ross, J F., D E. Handley, A S. Fix, G T. Lawhorn, and G J. Carr. n.d. “Quantification of the Hindlimb Extensor Thrust Response in Rats” 19:405–11.
Himes, Katherine P., Daniel Handley, Tianjiao Chu, Brian Burke, Kimberly Bunce, Hyagriv N. Simhan, and David G. Peters. 2012. “Comprehensive Analysis of the Transcriptional Response of Human Decidual Cells to Lipopolysaccharide Stimulation” 93:17–27.
Zhang, Yingze, Daniel Handley, Tommy Kaplan, Haiying Yu, Abha S. Bais, Thomas Richards, Kusum V. Pandit, et al. 2011. “High Throughput Determination of TGFβ1/SMAD3 Targets in A549 Lung Epithelial Cells” 6:e20319.
Rajakumar, A, T Chu, D E. Handley, K D. Bunce, B Burke, C A. Hubel, A Jeyabalan, and D G. Peters. 2011. “Maternal Gene Expression Profiling during Pregnancy and Preeclampsia in Human Peripheral Blood Mononuclear Cells” 32:70–78.
Chu, Tianjiao, Daniel Handley, Kimberly Bunce, Urvashi Surti, W A. Hogge, and David G. Peters. 2011. “Structural and Regulatory Characterization of the Placental Epigenome at Its Maternal Interface.” PloS One 6:e14723.
Pandit, Kusum V., David Corcoran, Hanadie Yousef, Manohar Yarlagadda, Argyris Tzouvelekis, Kevin F. Gibson, Kazuhisa Konishi, et al. 2010. “Inhibition and Role of Let-7d in Idiopathic Pulmonary Fibrosis.” American Journal of Respiratory and Critical Care Medicine 182:220–29.
Yu, Haiying, Melanie Königshoff, Aparna Jayachandran, Dan Handley, Werner Seeger, Naftali Kaminski, and Oliver Eickelberg. 2008. “Transgelin Is a Direct Target of TGF-Beta/Smad3-Dependent Epithelial Cell Migration in Lung Fibrosis” 22:1778–89.
Handley, Daniel, Nicoleta Serban, David G. Peters, and Clark Glymour. 2004. “Concerns about Unreliable Data from Spotted CDNA Microarrays Due to Cross-Hybridization and Sequence Errors.” Statistical Applications in Genetics and Molecular Biology 3:Article25.
Handley, Daniel, Nicoleta Serban, David Peters, Robert O’Doherty, Melvin Field, Larry Wasserman, Peter Spirtes, Richard Scheines, and Clark Glymour. 2004. “Evidence of Systematic Expressed Sequence Tag IMAGE Clone Cross-Hybridization on CDNA Microarrays” 83:1169–75.
Handley, D E., J F. Ross, and G J. Carr. 1998. “A Force Plate System for Measuring Low-Magnitude Reaction Forces in Small Laboratory Animals” 64:661–69.
Schmid, P, A Conrad, K Syndulko, E J. Singer, D Handley, X Li, G Tao, B Fahy-Chandon, and W W W. Tourtellotte. 1994. “Quantifying HIV-1 Proviral DNA Using the Polymerase Chain Reaction on Cerebrospinal Fluid and Blood of Seropositive Individuals with and without Neurologic Abnormalities” 7:777–88.

Professional Membership

Spring 2020 - Ongoing

American Society of Human Genetics, January 2020, Ongoing

Summer 2021 - Ongoing

American Society for Microbiology, August 2021, Ongoing

Fall 2022 - Ongoing

American Association for the Advancement of Science, April 2015, Ongoing

Summer 2020 - Ongoing

Pharmacogenomics Global Research Network, July 2020, Ongoing, The mission of the Pharmacogenomics Global Research Network (PGRN) is to catalyze and lead research in precision medicine for the discovery and translation of genomic variation influencing therapeutic and adverse drug effects.